期刊文献+

前列地尔联合丹参在微量蛋白尿期糖尿病肾病治疗中的价值 被引量:2

原文传递
导出
摘要 目的探讨前列地尔与丹参在微量蛋白尿期糖尿病肾病治疗中的价值。方法 2012年1月至2013年12月住院的53例糖尿病肾病患者,随机分为3组,对照组接受糖尿病肾病的标准治疗方案:糖尿病饮食、控制血糖、血压与血脂;前列地尔组在对照组的基础上加用20μg前列地尔静脉滴注;联合治疗组在前列地尔组治疗的基础上再加用丹参注射液20 ml静脉滴注。每日1次,连续14 d。对疗效的评价指标包括尿β2微球蛋白、24 h尿微量白蛋白水平、血脂及肾功能等。结果治疗后对照组患者尿β2微球蛋白、24 h尿微量白蛋白水平均较治疗前下降(P<0.05),联合治疗组与前列地尔组较治疗前下降更明显(P<0.01)。治疗后对照组患者血甘油三酯与胆固醇水平均较治疗前下降(P<0.05),联合治疗组与前列地尔组较治疗前下降更明显(P<0.01)。3组治疗前后血尿素氮与肌酐水平比较差异无统计学意义(P均>0.05)。结论前列地尔与丹参治疗有助于糖尿病肾病的病情改善,联合治疗效果优于单用前列地尔治疗。
出处 《中国临床研究》 CAS 2014年第12期1474-1476,共3页 Chinese Journal of Clinical Research
基金 江苏省南京医学科技发展项目(YKK13182)
  • 相关文献

参考文献12

  • 1Lim AKh. Diabetic nephropathy-complications and treatment [ J ]. tnt J Nephrol Renovasc Dis,2014,7:361 - 381.
  • 2Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective DiabetesStudy( UKPDS 64 ) [ J ]. Kidney Int, 2003,63 ( 1 ) : 225 - 232.
  • 3American Diabetes Association. Diagnosis and classification of diabe- tes mellitus [J]. Diabetes Care,2014,37 Suppl 1 :S81 -S90.
  • 4Molitch ME, DeFronzo RA, Franz M J, et al. Diabetic nephropathy [J]. Diabetes Care,2003,26 Suppl 1 :S94 -S98.
  • 5Mogensen CE, Schmitz A, Christensen CK. Comparative renal patho- physiology relevant to IDDM and NIDDM patients [ J ]. Diabetes Metab Rev, 1988,4 (5) :453 - 483.
  • 6Okada S,Iehiki K,Tanokuchi S,et al. Effect of prostaglandin El on the renin-aldosterone system in patients with diabetic nephropathy [ J ]. J Int Med Res, 1993,21 (3) : 126 - 132.
  • 7Shindo H, Tawata M, Inoue M, et al. The effect of prostaglandin El. alpha CD on vibratory threshold determined with the SMV-5 vibrom- eter in patientswith diabetic neuropathy [ J ]. Diabetes Res Clin Pracx, 1994,24 (3) : 173 - 180.
  • 8卢爱华,胡敏.前列腺素E_1在糖尿病慢性并发症中的应用研究[J].国外医学(内分泌学分册),2000,20(3):135-137. 被引量:110
  • 9张喆,于德民,赵伟,李淑颖.前列地尔对糖尿病肾病患者尿蛋白的影响[J].中国糖尿病杂志,2002,10(5):276-279. 被引量:146
  • 10Wang H, Deng JL, Yue J, et al. Prostaglandin E1 for preventing the progression of diabetic kidney disease [ J ]. Cochrane Database Syst Rev,2010(5) : CD006872.

二级参考文献30

  • 1郭芳,周国英.中西医结合治疗早期糖尿病肾病进展[J].实用中医药杂志,2006,22(3):186-187. 被引量:9
  • 2李勇,唐捷.前列地尔的药理研究进展[J].西南军医,2006,8(6):79-81. 被引量:70
  • 3[2]Sharma K,Ziyadeh F N.Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy[J].Semin Nephrol,1997,17(2):80-92.
  • 4[3]Weber K T,Fibrosis,a common pathway to organ failure:angiotensin Ⅱ and tissue repair[J].Semin Nephrol,1997,17(5):467-491.
  • 5[4]Ando T,Okuda S,Tamaki K,et al.Localization of transforming growth factor-beta and latent transforming growth factor-beta binding protein in rat kidney[J].Kidney Int,1995,47(3):733-739.
  • 6Young MJ, Veves A, Smith JV,et al. Restoring lower limb blood flow improves conduction velocity in diabetie patients. Diabetologia, 1995,38 :1051-1054.
  • 7Zoja C, Remuzzi G. Role of platelets in progrogressive glomerular disease. Pediatr Nephrol,1995. 495-502.
  • 8Saeki S,Yamamura K,Matsushita M, et al. Iontophoretic application of prostaglandin E1 for improvement in peripheral microcirculation. Int J Clin Pharmaeol Ther, 1998,36:529.
  • 9Okada S,Iehiki K, Tanokuehi S, et al. Effect of prostaglandin E1 on the renin-aldosterone system in patient with diabetic nephropathy. J Int Med Res, 1993,21 : 126-132.
  • 10Abe K, Ozono Y, Miyazak M, et al. Prostaglandin E1 for renal papillary necrosis in patients with diabetes mellitus. J Int Med Res, 1999,27:90-95.

共引文献259

同被引文献69

引证文献2

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部